Pharma steps up as coronavirus cases soar to 400,000-plusWith the coronavirus pandemic gathering momentum outside China, AstraZeneca has said it will donate 9 million face masks Share XPharma steps up as coronavirus cases soar to 400,000-plushttps://pharmaphorum.com/news/pharma-steps-up-as-coronavirus-cases-soar-to-400000-plus/
FDA approves ‘potential blockbuster’ migraine jab from LundbeckThe FDA has approved Lundbeck’s eptinezumab prophylactic treatment for migraine, the last from a gang of four drugs Share XFDA approves ‘potential blockbuster’ migraine jab from Lundbeckhttps://pharmaphorum.com/news/fda-approves-potential-blockbuster-migraine-jab-from-lundbeck/
Amgen, Allergan join Rituxan biosimilar challenge with FDA filingAmgen and Allergan have filed for approval of their biosimilar version of Roche’s CD20-targeting drug Rituxan with the Share XAmgen, Allergan join Rituxan biosimilar challenge with FDA filinghttps://pharmaphorum.com/news/amgen-allergan-join-rituxan-biosimilar-challenge-with-fda-filing/
UCB/Amgen’s Evenity approved in Europe after appealUCB and Amgen’s osteoporosis drug Evenity has finally been approved in Europe, following a successful appeal against a Share XUCB/Amgen’s Evenity approved in Europe after appealhttps://pharmaphorum.com/news/ucb-amgens-evenity-approved-in-europe-after-appeal/
Amgen strikes outcomes-based payment plan for Enbrel with AbarcaPharmacy benefit manager Abarca has announced a US reimbursement contract with Amgen for its Enbrel (etanercept) inflammatory diseases Share XAmgen strikes outcomes-based payment plan for Enbrel with Abarcahttps://pharmaphorum.com/news/amgen-strikes-outcomes-based-payment-plan-for-enbrel-with-abarca/
FDA finally approves Sandoz’s Neulasta biosimilar, but will Amgen put up a fight?The FDA has approved Sandoz’s pegfilgrastim biosimilar, a cheaper version of Amgen’s long-lasting and big-selling white blood cell Share XFDA finally approves Sandoz’s Neulasta biosimilar, but will Amgen put up a fight?https://pharmaphorum.com/news/fda-finally-approves-sandozs-neulasta-biosimilar-but-will-amgen-put-up-a-fight/
Amgen pays $2.7bn to harness BeiGene’s China marketing muscleFuelled by sweeping regulatory reforms and a massive ageing population, China is a key market for most big Share XAmgen pays $2.7bn to harness BeiGene’s China marketing musclehttps://pharmaphorum.com/news/amgen-pays-2-7bn-to-harness-beigenes-china-marketing-muscle/
Amgen pulls higher-priced Repatha to try to lift salesMore than four years after Amgen’s cholesterol-lowering antibody Repatha was approved in the US, the company still can’t Share XAmgen pulls higher-priced Repatha to try to lift saleshttps://pharmaphorum.com/news/amgen-pulls-higher-priced-repatha-to-try-to-lift-sales/
Patient voice overcomes EU ‘no’ for UCB/Amgen’s osteoporosis drugUCB/Amgen’s osteoporosis drug Evenity (romosozumab) looks set for approval in Europe after regulators finally recommended it, following a Share XPatient voice overcomes EU ‘no’ for UCB/Amgen’s osteoporosis drughttps://pharmaphorum.com/news/ucb-overcomes-eu-no-for-osteoporosis-drug-with-patient-testimony/
